VolitionRX (NYSEAMERICAN:VNRX) Stock Breaks Below 50 Day Moving Average – What’s Next?Defense World · Oct 17, 2026
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in FrancePRNewsWire · Sep 17, 2026
VolitionRx Participates in Launch of DETECSEPS Program in FrancePRNewsWire · Sep 17, 2026
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027PRNewsWire · Sep 14, 2026
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP ConferencePRNewsWire · Sep 10, 2026
VolitionRX (NYSEAMERICAN:VNRX) Share Price Crosses Below Fifty Day Moving Average – Here’s WhyDefense World · Sep 4, 2026VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.57 | -$0.85 | Miss |
| May 14, 2026 | -$0.70 | -$0.97 | Miss |
| Mar 31, 2026 | -$0.80 | -$1.05 | Miss |
| Nov 13, 2025 | -$0.80 | -$1.00 | Miss |
| Aug 14, 2025 | -$1.00 | -$1.20 | Miss |
| May 15, 2025 | -$0.86 | -$1.20 | Miss |